Thank you for Subscribing to Life Science Review Weekly Brief
Amgen is the world’s largest biotech company by market capitalization. The company is worth more than USD 134 billion and focuses on the discovery, development, manufacturing, and marketing of human therapeutics.
2. Gilead Sciences
Gilead Sciences is an American biotechnology company with a market cap of USD 78 billion that focuses on the research and development of antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and influenza.
An American multinational biotech company worth roughly USD 31 billion. The company mainly emphasises on discovery, development and delivery of treatments for neurological and neurodegenerative diseases such as Alzheimer's, Parkinson’s, multiple sclerosis etc.
Moderna, a new biotech company, has a market capitalization of USD 60 billion. This company has a pipeline of therapies using mRNA technology which includes cancer vaccines, regenerative therapeutics etc.
Founded in 1988, Regeneron Pharmaceuticals has a market capitalization of around USD74 billion and specialises in the invention, development, manufacture and commercialization of medicines. VelocImmune, Dupixent, Prauluent, Kevzara, ZALTRAP etc are some of the branded products of the company.
Another biotechnology company with a market capitalization of USD 69 billion, Vertex focuses on the discovery, development, manufacturing and commercialization of small molecule drugs used for serious ailments such as autoimmune diseases, cancer, etc.
Illumina is a fast-growing company that develops, manufactures and markets life science tools and integrated systems for the analysis of genetic variation and function. Its market capitalization is around USD 50 billion as of now.
BioMarin, with a market capitalization of USD 15 billion is a smaller biotech company. This company was the first of its kind to provide therapies for mucopolysaccharidosis type I and phenylketonuria.
9. Neurocrine Biosciences
Neurocrine Biosciences is another small biotech company with revenues of around USD 780 million. The development of treatments for neurological and endocrine-related diseases and disorders is the focus of the company.
10. SPDR S&P Biotech ETF
The SPDR S&P Biotech ETF (XBI) is a fund that already invests in biotech stocks to track the S&P Biotechnology Select Industry Index. The fund holds stocks in 163 biotechnology companies from large-capitalization to small capitalization.